{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:01:59Z","timestamp":1791302519603,"version":"4.1.0"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":1025,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1136\/esmoopen-2018-000357","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T08:55:51Z","timestamp":1525337751000},"page":"e000357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"special_numbering":"S1","title":["How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies"],"prefix":"10.1016","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct02441933","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01752686","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01752686","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02199418","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00813956","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00861705","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01426880","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02221999","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02441933","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01945775","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02032823","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03150576","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01074970","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01618357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03329937","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02032823","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03150576","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01042379","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01623349","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00761644","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02465060","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02593175","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02876107","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02511847","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01476137","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03025035","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02954874","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01042379","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02622074","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03036488","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02530489","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02620280","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02425891","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02819518","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02489448","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02926196","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02826434","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02900664","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01372579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01149083","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02322814","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ji Hyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hee","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2018-000357_bb0010","first-page":"649","article-title":"[Triple negative breast cancer: a difficult disease to diagnose and treat]","volume":"30","author":"Zaharia","year":"2013","journal-title":"Rev Peru Med Exp Salud Publica"},{"key":"10.1136\/esmoopen-2018-000357_bb0015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1309\/AJCPQN8GZ8SILKGN","article-title":"Triple-negative breast carcinoma: current and emerging concepts","volume":"141","author":"Schmadeka","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1136\/esmoopen-2018-000357_bb0020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10549-012-2315-y","article-title":"Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up","volume":"136","author":"Malorni","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0025","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s40265-013-0091-6","article-title":"Relapsed triple-negative breast cancer: challenges and treatment strategies","volume":"73","author":"Guarneri","year":"2013","journal-title":"Drugs"},{"issue":"Suppl 3","key":"10.1136\/esmoopen-2018-000357_bb0030","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1245\/s10434-010-1260-4","article-title":"Triple-negative breast cancers: unique clinical presentations and outcomes","volume":"17","author":"Billar","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0035","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1136\/esmoopen-2018-000357_bb0040","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0045","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0050","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1136\/esmoopen-2018-000357_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2018-000357_bb0060","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000357_bb0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000357_bb0075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"7","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000357_bb0080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"105","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000357_bb0085","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature11154","article-title":"Sequence analysis of mutations and translocations across breast cancer subtypes","volume":"486","author":"Banerji","year":"2012","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000357_bb0090","doi-asserted-by":"crossref","first-page":"e000208","DOI":"10.1136\/esmoopen-2017-000208","article-title":"How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment","volume":"2","author":"Saraiva","year":"2017","journal-title":"ESMO Open"},{"key":"10.1136\/esmoopen-2018-000357_bb0095","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/path.4280","article-title":"Identification and use of biomarkers in treatment strategies for\u00a0triple-negative breast cancer subtypes","volume":"232","author":"Lehmann","year":"2014","journal-title":"J Pathol"},{"key":"10.1136\/esmoopen-2018-000357_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/modpathol.2017.126","article-title":"Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer","volume":"31","author":"Adams","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1136\/esmoopen-2018-000357_bb0105","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"suppl 8","key":"10.1136\/esmoopen-2018-000357_bb0110","doi-asserted-by":"crossref","first-page":"viii13","DOI":"10.1093\/annonc\/mdt306","article-title":"BRCAness: a deeper insight into basal-like breast tumors","volume":"24","author":"De Summa","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0115","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2014.57.0085","article-title":"Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1 \/ 2 mutation\u2013associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105","volume":"33","author":"Telli","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0120","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nature07955","article-title":"CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle","volume":"459","author":"Yun","year":"2009","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000357_bb0125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng953","article-title":"BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair","volume":"32","author":"Hartman","year":"2002","journal-title":"Nat Genet"},{"key":"10.1136\/esmoopen-2018-000357_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.1381306","article-title":"Multifactorial contributions to an acute DNA damage response by BRCA1\/BARD1-containing complexes","volume":"20","author":"Greenberg","year":"2006","journal-title":"Genes Dev"},{"key":"10.1136\/esmoopen-2018-000357_bb0135","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood-2002-01-0278","article-title":"S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51","volume":"100","author":"Taniguchi","year":"2002","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2018-000357_bb0140","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0092-8674(00)81847-4","article-title":"Association of BRCA1 with Rad51 in mitotic and meiotic cells","volume":"88","author":"Scully","year":"1997","journal-title":"Cell"},{"key":"10.1136\/esmoopen-2018-000357_bb0145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"10.1136\/esmoopen-2018-000357_bb0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"4","author":"Narod","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0155","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/BST0340633","article-title":"Cellular functions of the BRCA tumour-suppressor proteins","volume":"34","author":"Boulton","year":"2006","journal-title":"Biochem Soc Trans"},{"key":"10.1136\/esmoopen-2018-000357_bb0160","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","article-title":"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage","volume":"95","author":"Yoshida","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1136\/esmoopen-2018-000357_bb0165","first-page":"1482","article-title":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","volume":"95","author":"Foulkes","year":"2003","journal-title":"CancerSpectrum Knowledge Environment"},{"key":"10.1136\/esmoopen-2018-000357_bb0170","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1038\/sj.onc.1209876","article-title":"Basal-like breast cancer and the BRCA1 phenotype","volume":"25","author":"Turner","year":"2006","journal-title":"Oncogene"},{"key":"10.1136\/esmoopen-2018-000357_bb0175","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Opinion: hallmarks of \u2019brcaness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccr.2009.07.011","article-title":"Targeting the molecular defect in brca-deficient tumors for Cancer Therapy","volume":"16","author":"Venkitaraman","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1136\/esmoopen-2018-000357_bb0185","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2011.02.061","article-title":"Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy","volume":"82","author":"Hattangadi-Gluth","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/esmoopen-2018-000357_bb0190","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0195","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/bjc.2014.444","article-title":"Predicting response and survival in chemotherapy-treated triple-negative breast cancer","volume":"111","author":"Prat","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0200","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S1470-2045(14)71104-0","article-title":"Radiation therapy in the locoregional treatment of triple-negative breast cancer","volume":"16","author":"Moran","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0205","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.14694\/EdBook_AM.2014.34.e32","article-title":"Should Triple-Negative Breast Cancer (TNBC) subtype affect local-regional therapy decision making?","volume":"34","author":"Moran","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1136\/esmoopen-2018-000357_bb0210","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2018-000357_bb0215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2018-000357_bb0220","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0225","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0230","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jnci\/djn089","article-title":"Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"10.1136\/esmoopen-2018-000357_bb0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-008-0081-7","article-title":"The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer","volume":"116","author":"Jones","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0240","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/annonc\/mdn761","article-title":"A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy","volume":"20","author":"Guarneri","year":"2009","journal-title":"Annals of Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.radonc.2011.07.007","article-title":"Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: A prospective randomized controlled multi-center trial","volume":"100","author":"Wang","year":"2011","journal-title":"Radiotherapy and Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0250","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0255","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0260","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.295.14.1658","article-title":"Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer","volume":"295","author":"Berry","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/esmoopen-2018-000357_bb0265","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/annonc\/mdm551","article-title":"Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial","volume":"19","author":"Gluz","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0270","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-014-2492-y","article-title":"A phase II study of metronomic paclitaxel\/cyclophosphamide\/capecitabine followed by 5-fluorouracil\/epirubicin\/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing\/HER2-negative primary breast cancer","volume":"74","author":"Masuda","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/esmoopen-2018-000357_bb0275","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1136\/esmoopen-2018-000357_bb0280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2017.02.024","article-title":"Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials","volume":"77","author":"Natori","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0285","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/jnci\/djh312","article-title":"The role of brca1 in the cellular response to chemotherapy","volume":"96","author":"Kennedy","year":"2004","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"10.1136\/esmoopen-2018-000357_bb0290","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer","volume":"33","author":"Isakoff","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0295","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer\u2014the road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2018-000357_bb0300","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0305","doi-asserted-by":"crossref","first-page":"P150","DOI":"10.1186\/1745-6215-16-S2-P150","article-title":"Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1\/2 breast cancer (BC)","volume":"16","author":"Tovey","year":"2015","journal-title":"Trials"},{"key":"10.1136\/esmoopen-2018-000357_bb0310","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0315","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","article-title":"Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients","volume":"147","author":"Byrski","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0320","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-008-0128-9","article-title":"Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients","volume":"115","author":"Byrski","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0325","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10549-015-3435-y","article-title":"Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)","volume":"151","author":"Kaklamani","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0330","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0335","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0340","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0345","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-16-3055","volume":"23","author":"Jovanovi\u0107","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0350","doi-asserted-by":"crossref","first-page":"60647","DOI":"10.18632\/oncotarget.10607","article-title":"Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2018-000357_bb0355","doi-asserted-by":"crossref","first-page":"55117","DOI":"10.1074\/jbc.M404524200","article-title":"Involvement of poly(adp-ribose) polymerase-1 and xrcc1\/dna ligase iii in an alternative route for dna double-strand breaks rejoining","volume":"279","author":"Audebert","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1136\/esmoopen-2018-000357_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0921-8777(00)00016-1","article-title":"Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?","volume":"460","author":"Shall","year":"2000","journal-title":"Mutat Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(00)00694-7","article-title":"Poly(APD-ribosyl)ation, a DNA damage-driven protein modification and regulator of genomic instability","volume":"163","author":"B\u00fcrkle","year":"2001","journal-title":"Cancer Lett"},{"key":"10.1136\/esmoopen-2018-000357_bb0370","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000357_bb0375","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000357_bb0380","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/emboj.2008.61","article-title":"A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor","volume":"27","author":"Turner","year":"2008","journal-title":"Embo J"},{"key":"10.1136\/esmoopen-2018-000357_bb0385","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2018-000357_bb0390","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1136\/esmoopen-2018-000357_bb0395","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1\/2 Mutations and Selected Sporadic Cancers","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1136\/esmoopen-2018-000357_bb0400","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2217\/fon-2016-0412","article-title":"A randomized Phase II study of veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in BRCA1 \/ 2 metastatic breast cancer: design and rationale","volume":"13","author":"Isakoff","year":"2017","journal-title":"Future Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0405","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-16-2714","article-title":"Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1 - or BRCA2 -associated metastatic breast cancer: california cancer consortium trial","volume":"23","author":"Somlo","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2017.08.013","article-title":"Phase I trial of veliparib, a poly ADP ribose polymerase inhibitor, plus metronomic cyclophosphamide in metastatic HER2-negative breast cancer","volume":"18","author":"Anampa","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0415","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1158\/1078-0432.CCR-15-2137","article-title":"Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and\/or brca mutation-associated breast cancer","volume":"22","author":"Rodler","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0420","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10637-016-0335-x","article-title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","volume":"34","author":"Kummar","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1136\/esmoopen-2018-000357_bb0425","doi-asserted-by":"crossref","first-page":"TPS1107","DOI":"10.1200\/jco.2015.33.15_suppl.tps1107","article-title":"A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and\/or metastatic breast cancer (EMBRACA)","volume":"33","author":"Litton","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0430","series-title":"PARTNER: Randomised, phase II\/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and\/or germline BRCA mutated breast cancer patients","author":"Helena Margaret Earl","year":"2017"},{"key":"10.1136\/esmoopen-2018-000357_bb0435","doi-asserted-by":"crossref","first-page":"S5-02","DOI":"10.1158\/0008-5472.SABCS13-S5-02","article-title":"Abstract S5-02: Veliparib\/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIAL:","volume":"73","author":"Rugo","year":"2013","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0440","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13058-017-0861-2","article-title":"The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting","volume":"19","author":"Severson","year":"2017","journal-title":"Breast Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0445","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/jco.2015.33.15_suppl.1082","article-title":"Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: final efficacy results of hoosier oncology group BRE09-146","volume":"33","author":"Miller","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0450","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.ajpath.2017.05.018","article-title":"Triple-negative breast cancer: next-generation sequencing for target identification","volume":"187","author":"Marotti","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1136\/esmoopen-2018-000357_bb0455","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2016.39","article-title":"Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology","volume":"29","author":"Weisman","year":"2016","journal-title":"Modern Pathology"},{"key":"10.1136\/esmoopen-2018-000357_bb0460","first-page":"3308","article-title":"[Effects of NVP-BKM120 on the triple-negative breast cancer cell]","volume":"95","author":"Zhang","year":"2015","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1136\/esmoopen-2018-000357_bb0465","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs brca1\/2 expression and sensitizes brca-proficient triple-negative breast cancer to parp inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1136\/esmoopen-2018-000357_bb0470","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2012.01.015","article-title":"Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition","volume":"319","author":"Kimbung","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1136\/esmoopen-2018-000357_bb0475","first-page":"3829","article-title":"Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib","volume":"35","author":"Yi","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0480","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdw562","article-title":"A randomized adaptive phase II\/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)","volume":"28","author":"Mart\u00edn","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0485","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1158\/1535-7163.MCT-15-0865","article-title":"Sensitizing triple-negative breast cancer to PI3K inhibition by cotargeting IGF1R","volume":"15","author":"de Lint","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/esmoopen-2018-000357_bb0490","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41523-017-0016-8","article-title":"Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer","volume":"3","author":"Solzak","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0495","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-12-1141","article-title":"Biomarkers of response to akt inhibitor mk-2206 in breast cancer","volume":"18","author":"Sangai","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0500","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3577","article-title":"A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors","volume":"15","author":"Hudis","year":"2013","journal-title":"Breast Cancer Research"},{"key":"10.1136\/esmoopen-2018-000357_bb0505","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","article-title":"Preclinical pharmacology of azd5363, an inhibitor of akt: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background","volume":"11","author":"Davies","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/esmoopen-2018-000357_bb0510","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0515","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/annonc\/mdu124","article-title":"Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer\u2020","volume":"25","author":"Gonzalez-Angulo","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0520","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jamaoncol.2016.5281","article-title":"Targeting the PI3K\/AKT\/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab","volume":"3","author":"Basho","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0525","first-page":"1609","article-title":"A perspective on anti-EGFR therapies targeting triple-negative breast cancer","volume":"6","author":"Nakai","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0530","doi-asserted-by":"crossref","first-page":"73618","DOI":"10.18632\/oncotarget.12037","article-title":"Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer","volume":"7","author":"El Guerrab","year":"2016","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2018-000357_bb0535","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/mc.22596","article-title":"Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells","volume":"56","author":"El Guerrab","year":"2017","journal-title":"Mol Carcinog"},{"key":"10.1136\/esmoopen-2018-000357_bb0540","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.112.111534","article-title":"Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor","volume":"54","author":"Al-Ejeh","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1136\/esmoopen-2018-000357_bb0545","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","article-title":"TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer","volume":"30","author":"Carey","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0550","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2012.46.2408","article-title":"Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer","volume":"31","author":"Baselga","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0555","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clbc.2014.07.007","article-title":"Ixabepilone alone or with cetuximab as first-line treatment for advanced\/metastatic triple-negative breast cancer","volume":"15","author":"Tr\u00e9dan","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0560","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clbc.2015.08.002","article-title":"N0436 (Alliance): a phase II trial of irinotecan with cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and\/or taxane-containing therapy","volume":"16","author":"Crozier","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0565","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clbc.2016.05.006","article-title":"Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a sarah cannon research institute phase II trial","volume":"16","author":"Yardley","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0570","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdu183","article-title":"Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline\/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact","volume":"25","author":"Nabholtz","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0575","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/ijc.29952","article-title":"Multicentric neoadjuvant pilot phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer","volume":"138","author":"Nabholtz","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0580","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","article-title":"In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models","volume":"15","author":"Hoeflich","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0585","doi-asserted-by":"crossref","first-page":"TPS1100","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS1100","article-title":"COLET (NCT02322814): a multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC)","volume":"34","author":"Miles","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0590","series-title":"Jos\u00e9 Angel Garc\u00eda Saenz. Cobimetinib (COBI) + paclitaxel (PTX) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Interim safety review of the ongoing phase 2 COLET study","first-page":"Poster 358","author":"Sung-Bae Kim","year":"2016"},{"key":"10.1136\/esmoopen-2018-000357_bb0595","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/neuonc\/nox052","article-title":"Combined kinase inhibitors of MEK1\/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer","volume":"19","author":"Van Swearingen","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0600","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.ejca.2013.03.020","article-title":"A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours","volume":"49","author":"Infante","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0605","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-014-2615-5","article-title":"Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma","volume":"75","author":"Tolcher","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/esmoopen-2018-000357_bb0610","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/annonc\/mdu482","article-title":"A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors","volume":"26","author":"Tolcher","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0615","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast Cancer Immunotherapy: Facts and Hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0620","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0625","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0630","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1038\/bjc.2013.634","article-title":"Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer","volume":"109","author":"Seo","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0635","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0640","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","article-title":"CD4\u207a follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Gu-Trantien","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1136\/esmoopen-2018-000357_bb0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079775","article-title":"Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial","volume":"8","author":"Issa-Nummer","year":"2013","journal-title":"PLoS One"},{"key":"10.1136\/esmoopen-2018-000357_bb0650","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0655","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0660","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0665","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10549-014-3185-2","article-title":"The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis","volume":"148","author":"Ibrahim","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0670","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0675","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-012-2245-8","article-title":"Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU\/epirubicin\/cyclophosphamide in breast cancer patients","volume":"136","author":"Oda","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0680","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials","volume":"26","author":"Dieci","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0685","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10549-011-1647-3","article-title":"CD8\u207a cytotoxic T cell and FOXP3\u207a regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes","volume":"130","author":"Liu","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0690","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-017-4499-7","article-title":"Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer","volume":"167","author":"Leon-Ferre","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0695","doi-asserted-by":"crossref","first-page":"Of10","DOI":"10.1158\/2159-8290.CD-NB2017-053","article-title":"Atezolizumab Extends Survival for Breast Cancer","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1136\/esmoopen-2018-000357_bb0700","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 Immune Checkpoint Inhibitors","volume":"22","author":"Loi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0705","doi-asserted-by":"crossref","DOI":"10.1007\/s12282-017-0781-0","article-title":"The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)","volume":"25","author":"Tomioka","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0710","doi-asserted-by":"crossref","first-page":"15584","DOI":"10.18632\/oncotarget.14698","article-title":"The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer","volume":"8","author":"Mori","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2018-000357_bb0715","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/cas.13114","article-title":"Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer","volume":"108","author":"Okabe","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1136\/esmoopen-2018-000357_bb0720","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jclinpath-2016-203990","article-title":"Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer","volume":"70","author":"Pol\u00f3nia","year":"2017","journal-title":"J Clin Pathol"},{"key":"10.1136\/esmoopen-2018-000357_bb0725","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-016-3786-z","article-title":"MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer","volume":"156","author":"Kim","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0730","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fonc.2017.00156","article-title":"Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions","volume":"7","author":"Wein","year":"2017","journal-title":"Front Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0735","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/annonc\/mdv571","article-title":"Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer","volume":"27","author":"Pruneri","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0740","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0745","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1158\/1078-0432.CCR-10-0505","article-title":"Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells","volume":"16","author":"Vonderheide","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0750","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-16-0190","article-title":"A pilot study of preoperative single-dose ipilimumab and\/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling","volume":"22","author":"McArthur","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0755","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1136\/esmoopen-2018-000357_bb0760","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000357_bb0765","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2017.35.15_suppl.1088","article-title":"Phase 2 study of pembrolizumab as first-line therapy for PD-L1\u2013positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B","volume":"35","author":"Adams","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0770","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2017.35.15_suppl.1008","article-title":"Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A","volume":"35","author":"Adams","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0775","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2018-000357_bb0780","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0959-8049(17)30131-4","article-title":"Phase 1b\/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer","volume":"72","author":"Tolaney","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2018-000357_bb0785","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1200\/JCO.2017.35.15_suppl.506","article-title":"Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2","volume":"35","author":"Nanda","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0790","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2017.35.15_suppl.556","article-title":"Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173","volume":"35","author":"Schmid","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2018-000357_bb0795","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2018-000357_bb0800","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920322651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920322651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2018-000357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:10Z","timestamp":1761855730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920322651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":159,"alternative-id":["S2059702920322651"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2018-000357","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2018-000357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000357"}}